Amgen may be way late to the obesity game, but the market scouts are loving the blockbuster potential of AMG 133
Amgen has been dangling another snapshot of early-stage data from its obesity drug AMG 133. And the analysts have been grabbing it and begging for more.
Cowen’s Yaron Werber reminds us in a note that Amgen got the process started with their business review for the anti-GIPR/GLP-1 peptide conjugate back in February. Then during an update for their AHA session, Amgen execs noted more dosing and “a 7.19-14.52% reduction in body weight (low vs high dose) by 12 weeks of treatment. Management confirmed the data is from on-treatment patients (which is notable as ITT obesity patients have historically shown 1-2% lower response), though dropouts were not high in the study thus far.”
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
